GlassScriptPhysician profile
Pedro Gabriel Mascaro
NPI 1851786461
$9,139.21
in general payments reported to CMS, 2019-2025
25 companies · $3,429 in 2025
The $3,429 reported for 2025 was more than what 87% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $250 · 2021: $396 · 2022: $710 · 2023: $1,596 · 2024: $2,323 · 2025: $3,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,811 · Travel and Lodging: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,810.79 |
| Travel and Lodging | $2,538.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,815.08 | 2022-2025 | Proclaim, Eterna, Durata |
| Boston Scientific Corporation | $2,609.57 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, Infinion 16 |
| Medtronic, INC. | $1,124.59 | 2021-2025 | Intellis Adaptivestim, Tyrx, Inceptiv |
| Vertos Medical, INC. | $629.39 | 2023-2024 | Mild Device Kit |
| Nevro Corp. | $596.03 | 2020-2024 | Senza |
| Globus Medical, INC. | $171.33 | 2025 | Vyrsa V1, Senza |
| Biotronik Nro, INC. | $169.28 | 2025 | Prospera |
| Stryker Corporation | $152.51 | 2021-2025 | Mild Device Kit |
| Si-Bone, INC. | $120.19 | 2024 | |
| Abbvie INC. | $115.27 | 2024-2025 | |
| Saluda Medical Americas, INC. | $113.89 | 2025 | Evoke |
| Medtronic USA, INC. | $98.37 | 2020 | |
| Protega Pharmaceutials INC | $70.71 | 2025 | Roxybond |
| Spr Therapeutics, INC | $60.71 | 2024 | Sprint Pns System |
| Relievant Medsystems, INC. | $57.09 | 2023 | Intracept |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $47.52 | 2025 | |
| Hikma Pharmaceuticals USA | $35.32 | 2022 | |
| Tersera Therapeutics LLC | $29.63 | 2019 | |
| Bioventus LLC | $23.75 | 2022 | |
| Amgen INC. | $22.66 | 2021 | |
| Painteq LLC | $16.57 | 2024 | Painteq |
| Kowa Pharmaceuticals America, INC. | $16.28 | 2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.17 | 2024 | Relistor |
| Valinor Pharma, LLC | $15.02 | 2025 | Movantik |
| Amneal Pharmaceuticals LLC | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Mascaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.